Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update

Company Achieves Multiple Clinical and Preclinical Milestones and Raises $9.7 Million in Non-Dilutive Funding, Eliminates Balance Sheet DebtIntroduces Novel Compound APVO711, Dual Mechanism of Action Includes

Related Keywords

Ukraine ,Russia ,Aptevo Therapeuticsview ,Miriam Weber Miller ,Marvin White ,Aptevo Biotherapeutics ,Development Expenses ,Company Phase ,Aptevo Therapeutics Inc ,Nasdaq ,Exchange Commission ,Company Achieves Multiple Clinical ,Pfizer ,Preclinical Milestones ,Non Dilutive Funding ,Eliminates Balance Sheet ,Dual Mechanism ,Action Includes Both Checkpoint Inhibitor ,Aptevo Therapeutics ,Chief Executive Officer ,Royalty Purchase Agreement ,Administrative Expenses ,Three Months Ended March ,Private Securities Litigation Reform Act ,Annual Report ,Gefallene Big Techs ,Aptevo ,Herapeutics ,Reports ,1q23 ,Financial ,Results ,Rovides ,Business ,Update ,